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Background: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is
associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian
cancers (EOCs) and its expression is higher in EOCs compared with non-malignant tissue. No data is currently available with
regard to the expression of SRC-3 in EOC and its influence on outcome or the efficacy of treatment.
Methods: Immunohistochemistry was performed for SRC3, oestrogen receptor-a, HER2, PAX2 and PAR6, and protein expression
was quantified using automated quantitative immunofluorescence (AQUA) in 471 EOCs treated between 1991 and 2006 with
cytoreductive surgery followed by first-line treatment platinum-based therapy, with or without a taxane.
Results: Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent
prognostic marker. High expression of SRC3 identified patients who have a significantly poorer survival with single-agent
carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen.
Conclusion: Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients
who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy.
Ovarian cancer is the second most common gynaecological cancer
but the most lethal, with over 200 000 cases diagnosed and 140 000
deaths worldwide per year (Ferlay et al, 2010), and in the majority
of cases presents with disease that has spread beyond the pelvis.
Surgical debulking and systemic chemotherapy with platinum/
taxanes are the mainstays of treatment, and despite treatment
advances the 5-year survival remains poor. There is good evidence
that platinum–taxane first-line chemotherapy is superior to other
chemotherapy regimens for ovarian cancer (Thigpen et al, 2011),
but 20–30% of patients do not respond to this therapy.
Experimental models of ovarian cancer have demonstrated that
expression of the oestrogen receptor-a (ERa) is associated with a
growth response to oestrogen, and in these models growth
inhibition occurs with anti-oestrogen both in vitro and in vivo
(Langdon et al, 1990, 1993, 1994a, b). In addition, within this
context oestrogen was shown to regulate a number of known
ER-regulated genes (Langdon et al, 1994a, b, 1998). Studies have
subsequently utilised endocrine therapy in the clinical setting in the
form of the selective oestrogen receptor modulator tamoxifen or
inhibition of aromatase. Response rates of 13–17% have been
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reported in ovarian cancer with tamoxifen (Hatch et al, 1991;
Ahlgren et al, 1993; Markman et al, 1996), while with aromatase
inhibitors radiological response rates of 0–15% and marker
response in 9–15% have been documented (Bowman et al, 2002;
del Carmen et al, 2003; Papadimitriou et al, 2004). Benefit
to treatment has been linked to a higher expression of ER
(Bowman et al, 2002), and a subsequent study, which selected
ovarian cancers based on an ER histoscore of 4150, found a
higher marker and radiological response rate with letrozole in
these cases as compared with previous studies (Smyth et al, 2007).
Furthermore, similar to breast cancer HER2 is lower in
endocrine-responsive ovarian tumours (Bowman et al, 2002;
Smyth et al, 2007).
Co-activators are essential for the transcriptional activation of
ligand-bound ER, and one such important cofactor is steroid
receptor coactivator 3 (SRC3), a member of the p160 steroid
receptor coactivator (SRC) family. Steroid receptor coactivator 3
has been showed to be amplified as well as have elevated expression
in malignant tissue as compared with normal tissue (Gojis et al,
2010a, b). It also has been shown to correlate with markers of
aggressive disease, such as increased Ki-67, larger tumours, lymph
node involvement, as well as being associated with a poorer
prognosis (Gojis et al, 2010a, b) and resistance to endocrine
resistance in breast cancer (Gojis et al, 2010b). Within the context
of breast cancer, chromatin immunoprecipitation-based assays
have shown that PARD6B/PAR6 and FER1L3 may be regulated by
SRC3 via ER (Labhart et al, 2005). In addition, SRC3 can compete
with PAX2 for binding to the HER2 cis-regulatory element, with a
resultant increase in HER2 transcription and cell proliferation
(Hurtado et al, 2008).
In sporadic ovarian cancer, amplification of SRC3 occurs in 25%
of cases, with none seen in familial cases (Tanner et al, 2000).
Amplification of SRC3 is associated with ER positivity and a
poorer overall survival (Tanner et al, 2000). In addition, the length
of the polyQ region within SRC3 has been associated with time to
disease recurrence and overall survival, with a short SRC-3 polyQ
genotype (o28 repeats) associated with reduced time to both these
events (Li et al, 2005). These data suggest a role for SRC3 in the
pathogenesis of sporadic ovarian carcinoma and a possible effect
on survival.
To date, the expression of SRC3 and its effect on outcome and
response to treatment have yet to be explored in ovarian cancer. In
this study, the expression of SRC3 in a cohort of ovarian cancers
was undertaken and its effect on outcome and response to
treatment investigated. In addition, the expression of ERa, HER2,
PAX2 and PAR6 were assessed.
PATIENTS AND METHODS
Patients. The study was approved by the Lothian Research Ethics
Committee (08/S1101/41). No informed consent (written or
verbal) was obtained for use of retrospective tissue samples from
the patients within this study, most of whom were deceased, as this
was not deemed necessary by the Ethics Committee. The study
population consisted of 471 FFPE ovarian tumours treated in the
Edinburgh Cancer Centre between 1991 and 2006, as described
previously (Faratian et al, 2011a, b). Summary patient character-
istics are shown in Table 1. Standard treatment included
cytoreductive surgery followed by platinum-based therapy, with
or without combination with a taxane.
Outcome. Overall survival was calculated from the date of
diagnosis (primary surgery) to the date of death by ovarian cancer,
or to the date of last follow-up (censored). Patients who died from
disease other than ovarian cancer were censored. Tumours were
taken from primary site (not metastatic) and before commence-
ment of chemotherapy.
Immunohistochemistry. Two tissue microarrays (TMAs)
containing 0.6-mm cores of tumours were constructed using
a previously described methodology (Graham et al, 2008).
Two tissue microarrays were manually stained in triplicate utilising
SRC3, ERa, HER2, PAX2 and PAR6 primary antibodies as detailed
in Table 2. All TMA tissue sections were incubated with the
primary antibodies for 1 h at room temperature. Protein expression
was quantified using AQUA. Immunofluorescence for protein
targets was performed using methods described previously
(Faratian et al, 2011a,b). Pan-cytokeratin antibody was used to
identify infiltrating tumour cells, DAPI counterstain to identify
nuclei and Cy-5-tyramide detection for target for compartmenta-
lised (tissue and subcellular) analysis of tissue sections.
Table 1. Clinicopathologic features of patients and first-line treatment
received for ovarian cancer
Characteristic No. Percent
Prognostic
significance
P-value
Number of patients 471 100
Age 0.059
Median age 60.4
Age range 27–86
First-line chemotherapy
regimen
0.04
Platinum-based 283 60.1
Platinum and taxane 175 37.2
Other/none 11 2.3
Unknown 2 0.4
Stage o0.0001
I 47 10.0
II 56 11.9
III 271 57.5
IV 78 16.6
Unknown 19 4.0
Histology o0.0001
Serous 264 56.1
Clear cell 24 5.1
Endometrioid 94 20
Mixed 61 13
MMMT 0 0
Mucinous 14 3.0
Other 12 2.5
Abbreviation: MMMT¼malignant mixed mesodermal tumor
Table 2. Primary antibodies used in this study
Primary
antibody Manufacturer
Catalogue
number Concentration
SRC3 BD Transduction
Laboratories
61105 1 : 50
ERa Neomarkers RM-9101-S1 1 : 50
HER2 Dako A0485 1 : 400
PAX2 Abcam 23799 1 : 400
PAR6 Abcam 57838 1 : 100
Abbreviations: ERa¼oestrogen receptor-a; SRC3¼ steroid receptor coactivator 3.
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Monochromatic images of each TMA core were captured at  20
objective using an Olympus AX-51 epifluorescence microscope
(Tokyo, Japan), and high-resolution digital images were analysed
by the AQUAnalysis software (HistoRx, Branford, CN, USA). If
the tumour epithelium comprisedo5% of total core area, the core
was excluded from analysis, to ensure adequate representation of
tissue.
Statistical analyses. Overall survival was assessed by
Kaplan–Meier analysis with log-rank testing to determine
statistical significance. Univariate and multivariate analyses were
performed using Cox proportional hazards regression models.
Comparison of differences in means was performed using the
Kruskal–Wallis test. To determine the cut-point value for each of
the phosphoproteins for Kaplan–Meier analysis, we utilised
X-Tile, which allows determination of an optimal cut-point while
correcting for the use of minimum P statistics, as described
previously (Camp et al, 2004). Two methods of statistical
correction for the use of minimal P approach were used, the first
calculation of a Monte Carlo P-value, and for the second, the
Miller–Siegmund minimal P correction (Altman et al, 1994).
All calculations and analyses were two-tailed, where appropriate,
and were carried out with SPSS 14.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Patient characteristics. Patient characteristics for the population
are summarised in Table 1. The median age for the cohort was 60.4
years (range, 27–86 years); 57.5% (271 out of 471) had stage III
Figure 1. Ovarian tumour core stained for SRC3: red¼ SRC3; green¼ cytokeratin; blue¼ nuclei; combined image¼ lower right.
Table 3. Correlation between protein concentrations of ER, HER-2, SRC-3, PAX-2 and PAR6
ERa HER-2 SRC3 PAX-2 PAR6
Correlation
coefficient
Significance
Correlation
coefficient
Significance
Correlation
coefficient
Significance
Correlation
coefficient
Significance
Correlation
coefficient
Significance
ERa 1.000 —  0.079 0.09 0.219 o0.001 0.200 o0.001 0.157 o0.001
HER-2  0.079 0.090 1.000 — 0.190 o0.001 0.172 o0.001 0.159 0.001
SRC3 0.219 o0.001 0.190 o0.001 1.000 — 0.249 o0.001 0.127 0.008
PAX-2 0.200 o0.001 0.172 o0.001 0.249 o0.001 1.000 — 0.382 o0.001
PAR6 0.157 0.001 0.159 o0.001 0.127 0.008 0.382 o0.001 1.000 —
Abbreviations: ERa¼oestrogen receptor-a; SRC3¼ steroid receptor co-activator 3.
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tumours and 56% (264 out of 471) had serous type tumours. With
regard to first-line treatment, 60% (283 out of 471) received
platinum-based treatment, and 37% (175 out of 241) a platinum-
taxane doublet.
Correlation of SRC3 with clinicopathological features and other
biological parameters. With respect to histopathological para-
meters, SRC3 expression was significantly higher in stage III and
stage IV tumours (Kruskal–Wallis test, Po0.001) and lower in
endometrioid carcinomas when compared with other histological
subtypes (Kruskal–Wallis test, Po0.001). Oestrogen receptor was
significantly higher in stages III and IV (P¼ 0.031), and lower in
clear-cell carcinomas (Kruskal–Wallis test, Po0.0001); and
HER2 was significantly higher in clear-cell and mixed cancers
(Kruskal–Wallis test, P¼ 0.025). Weak but significant correlations
were seen between SRC3 and ERa, HER-2, PAX-2 and PAR6
(Figure 1 and Table 3).
SRC3 and outcome. High expression of SRC3 (as assessed by
AQUA) identified patients who have a significantly worse overall
survival (Figure 2; P-valuep0.001, Miller–Siegmund P-value¼
0.0029, Monte-Carlo P-value o0.0001). With multivariate
analysis, we identified ERa and SRC3 expressions as independent
prognostic factors. Stage (Po0.001, relative risk¼ 1.865),
ER expression (Po0.001, relative risk¼ 0.500), SRC3 expression
(P¼ 0.015, relative risk¼ 1.349) and treatment regimen (P¼ 0.025,
relative risk¼ 0.783).
Expression of SRC3 and outcome of first-line chemotherapy.
Expression of SRC3 identified patients who have a significantly
improved survival when treated with single-agent carboplatin
chemotherapy (Po0.001) (Figure 3a), with patients with low SRC3
having a better survival when treated with single carboplatin as
compared to those with a high expression. In patients treated with
the combination of carboplatin and paclitaxel, this difference is no
longer seen in patients with low and high expression having a
similar outcome (Figure 3b).
DISCUSSION
This is the first time that data relating to the expression of SRC3 in
the context of ovarian cancer and its potential as a prognostic and
treatment-predictive marker have been explored. As in other
tumour types, high expression of SRC3 was associated with more
advanced tumours (Gojis et al, 2010a, b), and the significant
association with stage of disease is in keeping with the known role
of SRC3 in cell motility and invasion (Bai et al, 2000; Li et al,
2008a, b), which is known to involve focal adhesion turnover
and focal adhesion kinase activation (Qin et al, 2008), as well as
upregulation of the expression of matrix metalloproteinase
(Qin et al, 2008).
The role of SRC3 as a predictive factor in the response to
oncological therapies has been previously explored in the context
of endocrine therapy (particularly tamoxifen in breast cancer), but
no previous reports have explored its importance in systemic
cytotoxic treatments. With regard to tamoxifen and breast cancers,
differing results have been reported with reference to SRC3 and its
predictive nature. In a retrospective series of breast cancers, high
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SRC3 in the presence of tamoxifen was a negative prognostic factor
(Osborne et al, 2003). However, other retrospective series have
found it associated with recurrence on tamoxifen but not with
long-term outcome (Dihge et al, 2008) or its expression alone had
no influence on disease-free survival in tamoxifen-treated patients
(Kirkgaard et al, 2007). In the context of premenopausal women,
who entered into a randomised study of tamoxifen vs no
tamoxifen, high SRC3 in the presence of tamoxifen treatment
was associated with a significantly better disease-free survival
(Alkner et al, 2010). The reasons for these disparate results are
likely to be related to patient heterogeneity as well as methodo-
logical issues. In the current cohort, high SRC3 was associated with
a significantly poorer overall survival when single-agent carbopla-
tin was utilised as first-line therapy compared to those with low
SRC3. In those patients receiving the doublet carboplatin/
paclitaxel, there was no difference in outcome based on SRC3
expression. These data would suggest that SRC3 is a potential
marker for resistance to single-agent platinum therapy and could
be used to identify cases of ovarian cancer that could benefit from
carboplatin/paclitaxel combination therapy. The underlying
mechanism for the involvement of SRC3 in resistance to single-
agent platinum could be via its effect on insulin-like growth factor
(IGF) signalling. It has been previously shown that increased
IGF-1R mRNA expression is linked with resistance to cisplatin,
and IGF-1R mRNA expression has been found to be strongly
correlated with intrinsic cisplatin resistance status in a panel of
human ovarian cancer cells (Eckstein et al, 2009). Steroid receptor
coactivator 3 is known to maintain IGF-I in the circulation (Liao
et al, 2008), and in the context of human breast cancer mediates
the effects of IGF-1-induced proliferation, signalling and cell
survival (Oh et al, 2004). Furthermore, SRC3 is known to be
phosphorylated by IGF-1 at tyrosine 1357, which contributes to it
oncogenic behaviour (Oh et al, 2008). Therefore, it could be
hypothesised that the effects of SRC-3 seen in this report are
mediated in an IGF-1/IGFR-dependent manner.
A number of large randomised studies have explored the
efficacy of paclitaxel in combination with platinum against a
platinum-based control treatment as first-line treatment for
ovarian cancer. However, only the third International Collabora-
tive Ovarian Neoplasm study (ICON 3) (ICON, 2002) and
Gynecology Oncology Group-132 (GOG-132) (Muggia et al,
2000) included a randomisation to platinum alone, and in these
studies the outcome with paclitaxel/platinum doublet was
equivalent to platinum alone. Given the data presented here, it
would be of interest to explore the expression of SRC3 and its
influence on outcome in cases entered into ICON3 and GOG-132
to confirm its potential usefulness as a potential biomarker for
treatment selection.
This study, although it is based on a well-defined and large cohort
of 471 patients, which were carefully followed up, is limited by the
fact that it is a single-centre retrospective study. Furthermore, given
we were unable to explore the potential efficacy of taxane alone.
Therefore, these findings need to be explored in the context of
ICON 3 (ICON, 2002) and GOG-132 (Muggia et al, 2000).
In summary, SRC3 is a poor prognostic factor in ovarian
epithelial cancers and appears to identify patients who would
benefit from the addition of taxanes to their platinum-based first-
line treatment. Further studies of prospective randomised studies
are required.
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